RIGL
Closed
Rigel Pharmaceuticals Inc
18.71
-0.02 (-0.11%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 18.73
Day's Range: 18.24 - 19.02
Send
sign up or login to leave a comment!
When Written:
1.23
Rigel Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of novel small-molecule drugs for the treatment of immune and hematologic disorders, as well as cancer. The company was founded in 1996 and is headquartered in South San Francisco, California.
Rigel's lead product is fostamatinib, which is an oral spleen tyrosine kinase (SYK) inhibitor that is currently approved for the treatment of chronic immune thrombocytopenia (ITP) in adults. The company is also developing fostamatinib for the treatment of autoimmune hemolytic anemia (AIHA), IgA nephropathy, and other immune and hematologic disorders.
In addition to fostamatinib, Rigel is developing a pipeline of small-molecule drugs that target various signaling pathways involved in immune and hematologic disorders. These include R835, a receptor interacting protein kinase (RIPK) inhibitor for the treatment of inflammatory disorders, and R552, a dual spleen tyrosine kinase (SYK) and Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases.
Rigel has collaborations with several pharmaceutical companies, including AstraZeneca, Daiichi Sankyo, and Eli Lilly, to develop and commercialize its products. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol RIGL.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Rigel's lead product is fostamatinib, which is an oral spleen tyrosine kinase (SYK) inhibitor that is currently approved for the treatment of chronic immune thrombocytopenia (ITP) in adults. The company is also developing fostamatinib for the treatment of autoimmune hemolytic anemia (AIHA), IgA nephropathy, and other immune and hematologic disorders.
In addition to fostamatinib, Rigel is developing a pipeline of small-molecule drugs that target various signaling pathways involved in immune and hematologic disorders. These include R835, a receptor interacting protein kinase (RIPK) inhibitor for the treatment of inflammatory disorders, and R552, a dual spleen tyrosine kinase (SYK) and Janus kinase (JAK) inhibitor for the treatment of autoimmune diseases.
Rigel has collaborations with several pharmaceutical companies, including AstraZeneca, Daiichi Sankyo, and Eli Lilly, to develop and commercialize its products. The company is publicly traded on the NASDAQ stock exchange under the ticker symbol RIGL.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








